The choice between bariatric surgery and GLP-1 receptor agonists for the treatment of severe obesity should be personalized based on individual patient characteristics, preferences, and clinical circumstances. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.